PCSK9 and familial hyperaldosteronism: Also, Lp(a) concentrations were reported to be higher in patients with FH (LDLR and PCSK9 mutations) compared with controls (Tada et al., 2016), and Lp(a) levels are modestly lowered by PCSK9 inhibitors (Bittner et al., 2020; O'Donoghue et al., 2019).